EliseAI invests in Sapphire Ventures
Funding Provisional 90% confidence first seen
EliseAI (Elise A.I. Technologies Corp.) raised $350 million to expand its AI work automation suite for real-estate and healthcare customers, valuing the company at $4 billion. The round was led by Andreessen Horowitz and Bessemer and included participation from Sapphire Ventures along with Ontario Teachers’ Pension Plan and Navitas Capital. The investment matters because it provides additional capital to extend EliseAI’s automation features and scale hiring across engineering, deployment, and sales.
The deal
EliseAI $350 million Late stage · announced 29 Sep 2026
Investors Andreessen Horowitz Bessemer Bessemer Venture Partners Ontario Teachers’ Pension Plan
Deal terms as reported in the coverage below.
Decision brief
- What changed
- EliseAI raised $350 million in a funding round led by Andreessen Horowitz and Bessemer, with participation from Sapphire Ventures, Ontario Teachers’ Pension Plan, and Navitas Capital, at a reported $4 billion valuation. The company said it will use the capital to expand its AI work automation suite for real-estate and healthcare customers and to hire across engineering, deployment, and sales.
- Why it matters
- For leaders in real estate and healthcare, this funding increases the likelihood that EliseAI can broaden product capabilities and customer-facing capacity in categories where workflow automation can affect operating efficiency and service delivery. For competing vendors and enterprise buyers, the round signals that well-funded AI automation providers may accelerate feature expansion and go-to-market activity, which can influence vendor selection timelines, pricing leverage, and partnership decisions.
- Evidence
- The provided coverage comes from a single SiliconANGLE article, which reports the $350 million raise, the $4 billion valuation, the investor group, and EliseAI’s stated plans to expand automation features and hiring. Because the brief relies on one report and company-stated intentions, the factual core is supported but not independently corroborated across multiple outlets in the materials provided.
- What remains uncertain
- The coverage does not specify product roadmap timing, expected revenue impact, customer growth, or how the new capital will be allocated across real estate versus healthcare. It also does not verify whether the planned hiring and feature expansion will translate into measurable deployment gains, competitive advantage, or ROI for customers.
- Monitor next
- Watch for EliseAI’s next concrete product releases or disclosed customer deployments in real estate and healthcare that show how the new funding is being converted into expanded automation capabilities.
Analytical support, not advice — assumptions and open questions stated above.